The PTEN and RB gene sets were altered in 18.3% and 8.2% of cases, respectively (Fig. 3A–B), despite the relatively low frequency of PTEN and CDKN2A mutations in ccRCC patients (Fig. 3C–D). This evidence concerns the gene RB1 and nonpapillary renal cell carcinoma.